Home » vWF-A1 Products

We're moving to rndsystems.com. Come with us!

After August 17, 2026, Novus Biologicals products and services will no longer be available on this website; you will access all products and services on rndsystems.com. Create your R&D Systems online account today.

Register on R&D Systems

vWF-A1 Products


Description

Caplacizumab is a humanized VHH immunoglobulin that binds to the A1 domain of the large von Willdebrand factor resulting in the inhibition of the interaction of glycoprotein GPIb-IX-V receptor on platelet surface.  The result of neutralizing of the von Willedebrand factor is reduced platelet aggregation.  Caplacizumab has been approved for the treatment of acute thrombotic thrombocytopenic purpura (aTTP), and has been shown to reduce the occurrence of thromboembolic events.

Bioinformatics

Product By Gene ID 7450
Alternate Names
  • vWFA1
  • vWF-A1